Showing 1861-1870 of 9129 results for "".
Calling Out Hesitation on Systemics
https://practicaldermatology.com/programs/practical-dermatology/calling-out-hesitation-on-systemics/35703/The latest news and updates, plus Jason E. Hawkes, MD, MS, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss why dermatologists should not be reluctant to prescribe systemic therapies, and Linda F. Stein Gold, MD, discusses the importance of an ever-expanding aAnalyzing Safety Data From Level Up
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 3
https://practicaldermatology.com/videos/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-3/32759/Host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, discuss the importance of patients acting at the first sign of flare with generalized pustular psoriasis, and the risks of serious illness and mortality.Analysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/videos/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discussesFDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.Science of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts oNoah Worcester 2024: Dr. Bettencourt on Beach Vacations
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bettencourt-beach-vacations/24591/Miriam Bettencourt, MD, summarizes her lecture about problems that can be encountered during beach vacations at the 2024 Noah Worcester Dermatological Society meeting.Revealed: The Two Hottest New Skin Cancer Ingredients
https://practicaldermatology.com/conferences/scale-2023/revealed-the-two-hottest-new-skin-cancer-ingredients/20202/Todd Schlesinger, MD, discusses the growing role of exosomes and cannabidiol (CBD) in dermatology.Advances in Topicals for Skin Conditions
https://practicaldermatology.com/topics/psoriasis/advances-in-topicals-for-skin-conditions/20197/There are more topicals available today than ever before for acne, rosacea, and psoriasis, and even more are coming down the pike. Larry Green, MD, reviews the current topical landscape in dermatology and previews what’s in the pipeline.Women and Acne: Special Considerations
https://practicaldermatology.com/conferences/scale-2023/women-and-acne-special-considerations/20189/Julie C. Harper, MD, discusses the role that oral contraceptives and spironolactone play in treating female acne and reviews some of the potential risks of these therapies.